Tag: viral load

Dolutegravir Confirmed as Effective Second-Line HIV Therapy

Dolutegravir and ritonavir-boosted darunavir are equally effective second-line treatments for HIV-1, even for patients with resistance to nucleoside reverse-transcriptase inhibitors (NRTIs) in the regimen, a...

Monkeys May Lead the Way for Immunotherapy HIV Cure

A small study conducted in rhesus macaques found a 10-fold reduction in HIV viral load when the monkeys received immunotherapy to block programmed cell death...

Lenacapavir Shows Viral Suppression in Drug-Resistant HIV

Dr Jean-Michel Molina The long-acting drug lenacapavir, a first-in-class capsid inhibitor, shows sustained viral suppression in a small cohort of heavily treatment-experienced patients with multidrug-resistant...

HIV Increases Risk for Severe COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. HIV increases the risk for severe COVID-19 by 6% and the...

Another HIV Tivicay Birth Outcome: Better Infant Survival

Infants born to women with HIV who were taking dolutegravir (DTG) plus emtracitabine/tenofovir alafenamide (FTC/TAF) had significantly higher odds of surviving the first 6 months...

Data ‘Favorable’ That Vaccines Limit Transmission

Researchers know by now the available COVID-19 vaccines prevent people from getting COVID around 95% of the time. But the million-dollar question remains: Are people...

COVID-19 Immunity Could Last Longer Than 8 Months, Study Says

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Certain antibodies and memory cells likely last more than 8 months...

New Mutation Sped Up Spread of Coronavirus

Nov. 13, 2020 — The virus that causes COVID-19 is not the same strain as what first emerged from China. A new study shows it...

Two COVID-19 Outpatient Antibody Drugs Show Encouraging Results

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Two COVID-19 antibody treatments, one developed by Regeneron and the other...

Once-Weekly Investigational MK-8507 Potent Even at Low Doses

A single dose of MK-8507, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), reduced HIV-1 viral loads for at least 1 week with efficacy comparable to...

First Confirmed U.S. Cases of COVID Reinfections

Oct. 12, 2020 — A 25-year-old man from Nevada and a 42-year-old man in Virginia experienced second bouts of COVID-19 about 2 months after they...

Trump No Longer Infectious, His Doctor Says

President Donald Trump is “no longer considered a transmission risk to others” for the coronavirus, according to a memo from his doctor released on Saturday...

Severe COVID Clues: Autoantibodies, Gene Mutations

Sept. 25, 2020 — Since the beginning of the COVID-19 pandemic, scientists have struggled to find out why some people who get COVID-19 develop severe...

COVID-19 Update: Fatality Rate, Dog Detectives

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Here are the coronavirus stories Medscape’s editors around the globe think...

Higher Viral Loads Seen in Less Severe COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Testing in the emergency department (ED) at a New York City...

Unexpected Viral Load, Early HCQ No Help

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Here are the coronavirus stories Medscape’s editors around the globe think...

Brazilian Patient in HIV Remission, Negative Antibody Test

A 35-year-old Brazilian man who participated in a trial in which he received an intensified antiretroviral regimen plus supplemental vitamin B₃ for 48 weeks has joined...

Doctor With COVID-19 Recovering After Treatment, “Lot of Luck”

Dr Alberto Bassi, a 62-year-old Italian dermatologist, was still hospitalized in the town of Castel San Giovanni in Piacenza, Italy, and on oxygen when he...